Last reviewed · How we verify
Sofosbuvir/Velpatasvir + Ribavirin
Sofosbuvir inhibits hepatitis C virus NS5B polymerase, velpatasvir inhibits NS5A protein, and ribavirin has broad antiviral activity, together blocking HCV replication.
Sofosbuvir inhibits hepatitis C virus NS5B polymerase, velpatasvir inhibits NS5A protein, and ribavirin has broad antiviral activity, together blocking HCV replication. Used for Chronic hepatitis C virus infection (genotypes 1-6), Hepatitis C in treatment-experienced patients.
At a glance
| Generic name | Sofosbuvir/Velpatasvir + Ribavirin |
|---|---|
| Also known as | Epclusa |
| Sponsor | Peking University People's Hospital |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B polymerase, HCV NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir is a nucleotide analog that directly inhibits the HCV NS5B RNA-dependent RNA polymerase, preventing viral RNA synthesis. Velpatasvir is a pangenotypic NS5A inhibitor that disrupts viral replication and assembly. Ribavirin is a nucleoside analog with broad antiviral properties that enhances the effect of the direct-acting antivirals. This triple combination targets multiple steps of the HCV lifecycle.
Approved indications
- Chronic hepatitis C virus infection (genotypes 1-6)
- Hepatitis C in treatment-experienced patients
Common side effects
- Fatigue
- Headache
- Nausea
- Anemia (ribavirin-related)
- Insomnia
Key clinical trials
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy (PHASE4)
- The Efficacy of Vosevi in Treating DAA-experienced Patients
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
- Hepatitis C Positive Donor Into Hepatitis C Negative Recipients (EARLY_PHASE1)
- Transplanting Hepatitis C Lungs Into Negative Lung Recipients (PHASE1, PHASE2)
- HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial (PHASE4)
- Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders (PHASE4)
- Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: